Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.
The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.
New Wage Code Comes Into Force, Expands Coverage & Strengthens Worker Protection; Aims To Boost Fairness | Explained
'Attempt To Strip Punjab Of Its Rights Over Chandigarh': AAP's Arvind Kejriwal Opposes Constitution (131st Amendment) Bill
Family Members of Wing Commander Namansh Syal Get Emotional As His Mortal Remains Arrive At Kangra Airport In Himachal Pradesh – VIDEO
'Don't Want To Lose Dignity...': Ranbir Kapoor's OLD Video Refusing To Dance At Weddings Goes Viral After Celebs Perform At Udaipur Wedding
.png)
